TuHURA Biosciences, Inc.
HURA · NASDAQ
9/30/2025 | 6/30/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.08 | -6.43 |
| FCF Yield | 0.00% | -11.11% | -1.51% | -12.69% |
| EV / EBITDA | 0.00 | -9.60 | -29.45 | -5.44 |
| Quality | ||||
| ROIC | 0.00% | -49.66% | -38.49% | 171.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.43 | 0.87 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | -38.75% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.84 | 2.28 | 1.39 |
| Interest Coverage | 0.00 | 0.00 | -10.89 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.08 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -14,994.64 | 0.00 |